abstract |
The present invention relates to the use of dual antagonists comprising CCR2/5, such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazole) [1,5-a][1,3,5]triazin-4-ylamino)-2-oxypyrrolidin-1-yl)cyclohexyl)acetamide; monoclonal antibodies such as nivolumab and/or a method of treating cancer in a subject with a combination of chemotherapy. |